Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

计划入组 1,300 人 · 首次发布于 2025 年 6 月 5 日

Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

计划入组 88 人 · 首次发布于 2026 年 5 月 26 日

Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia

计划入组 26 人 · 首次发布于 2026 年 8 月 17 日

AML-3

AML-4

AML(Exiris)

BEAT AML, LLC

United States

R&R, Inc.

United States

Anabio R&D

Vietnam

Forskolin Shows Dual Mechanism Against Aggressive KMT2A-Rearranged Acute Myeloid Leukemia

Ziftomenib Shows Promise in AML: Kura Oncology and Kyowa Kirin Advance to Phase 3 Trials

Kura Oncology Announces Q3 2024 Financial Results and Pipeline Updates